Lista de obras -

A fuzzy logic-based system for anaesthesia monitoring

artículo científico publicado el 1 de enero de 2010

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

artículo científico publicado en 2014

A phase 3 trial of bevacizumab in ovarian cancer ⬇️

artículo científico publicado en 2011

A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

scientific article published on 02 August 2019

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

artículo científico publicado en 2010

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

artículo científico publicado en 2016

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

artículo científico publicado en 2014

Cancer of the corpus uteri

artículo científico publicado en 2018

Cancer of the corpus uteri

scientific article published on 01 October 2012

Cancer of the corpus uteri.

artículo científico publicado en 2015

Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects

scientific article published on 01 January 2019

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer

artículo científico publicado en 2017

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

artículo científico publicado en 2016

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

artículo científico publicado en 2016

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

scientific article published on 18 December 2020

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up

artículo científico publicado en 2016

ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

artículo científico publicado en 2015

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer

scientific article published on 11 August 2011

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

scientific article published on 09 January 2019

European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies

artículo científico publicado en 2010

European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groupsand industry partners - a new Model D for drug and medical device development

artículo científico publicado en 2020

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

artículo científico publicado en 2015

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

artículo científico publicado en 2017

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).

artículo científico publicado en 2014

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

artículo científico publicado en 2019

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

artículo científico publicado en 2016

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

artículo científico publicado en 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma

artículo científico publicado en 2014

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer

artículo científico publicado en 2011

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

artículo científico publicado en 2020

Incorporation of pazopanib in maintenance therapy of ovarian cancer

artículo científico publicado en 2014

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

artículo científico publicado en 2016

Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement

artículo científico publicado en 2019

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

artículo científico publicado en 2020

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

artículo científico publicado en 2020

Major clinical research advances in gynecologic cancer in 2017.

artículo científico publicado en 2018

Major clinical research advances in gynecologic cancer in 2018

scientific article published on 01 March 2019

Major clinical research advances in gynecologic cancer in 2019

artículo científico publicado en 2020

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

artículo científico publicado en 2023

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

scientific article published on 07 June 2019

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

artículo científico publicado en 2016

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

scientific article published on 16 September 2019

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

artículo científico publicado en 2019

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

scientific article published on 29 August 2019

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

artículo científico publicado en 2014

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

scientific article published on 15 August 2019

Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study

artículo científico publicado en 2009

Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer

scientific article published on 23 May 2019

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)

artículo científico publicado en 2020

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

artículo científico publicado en 2024

Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).

artículo científico publicado en 2007

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

artículo científico publicado en 2018

Regulatory CD8+CD28- T cells in heart transplant recipients.

artículo científico publicado en 2003

Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment

artículo científico publicado en 2020

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

artículo científico publicado en 2011

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM) ⬇️

artículo científico publicado en 2014

Shall we settle for low-level evidence?

artículo científico publicado en 2014

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial ⬇️

artículo científico publicado en 2015

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

artículo científico publicado en 2015

Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.

artículo científico publicado en 2014

Survival and failure types after radiation therapy of vulvar cancer.

artículo científico publicado en 2017

The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers

scientific article published on 12 August 2019

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

artículo científico publicado en 2015

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities

artículo científico publicado en 2018

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

artículo científico publicado en 2023

The value of gynecologic cancer follow-up: evidence-based ignorance?

artículo científico publicado en 2010

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

artículo científico publicado en 2020

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

artículo científico publicado en 2019

[Picture of the month: recurrent cervix cancer, hydronephrosis, affected renal function, bladder hematoma].

artículo científico publicado en 2002

Lista de obras de

A fuzzy logic-based system for anaesthesia monitoring

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

A phase 3 trial of bevacizumab in ovarian cancer ⬇️

A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

Cancer of the corpus uteri

Cancer of the corpus uteri

Cancer of the corpus uteri.

Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up

ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies

European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groupsand industry partners - a new Model D for drug and medical device development

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Incorporation of pazopanib in maintenance therapy of ovarian cancer

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Major clinical research advances in gynecologic cancer in 2017.

Major clinical research advances in gynecologic cancer in 2018

Major clinical research advances in gynecologic cancer in 2019

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study

Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Regulatory CD8+CD28- T cells in heart transplant recipients.

Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM) ⬇️

Shall we settle for low-level evidence?

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial ⬇️

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.

Survival and failure types after radiation therapy of vulvar cancer.

The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

The value of gynecologic cancer follow-up: evidence-based ignorance?

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

[Picture of the month: recurrent cervix cancer, hydronephrosis, affected renal function, bladder hematoma].

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial